Southborough, MA – June 16, 2025 — Veristat, a leading global clinical research organization (CRO) and consultancy, proudly congratulates George Medicines on the U.S. Food and Drug Administration (FDA) approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a novel single pill combination treatment for hypertension in adults, including as initial treatment, to lower blood pressure.   

The approval of WIDAPLIK™ marks a significant milestone for George Medicines and the patients who will benefit from this innovative treatment. Veristat is honored to have played a role in supporting George Medicines throughout their pivotal trial and the regulatory journey, providing comprehensive statistical consulting, biometrics expertise and strategic guidance in FDA interactions. 

“We are thrilled to see WIDAPLIK™ receive FDA approval,” said Patrick Flanagan, CEO of Veristat. “This achievement reflects the dedication and collaboration between our teams and underscores Veristat’s commitment to helping bring life-changing therapies to market. We are humbled to be a part of this great advancement for patients with hypertension.” 

George Medicines expressed deep appreciation for Veristat’s partnership during the development and approval process of this novel therapy. 

“This approval underscores the power of true collaboration in advancing science and improving lives,” said Robin Bliss, PhD, Vice President of Strategic Consulting at Veristat. “We are proud to have supported George Medicines on their journey, and we remain committed to helping biopharmaceutical innovators bring transformative therapies to patients around the world.”